DEPARTMENT OF THE AIR FORCE
HEADQUARTERS UNITED STATES AIR FORCE WASHINGTON, DC
DAFMAN44-197_DAFGM2022-01
23 SEPTEMBER 2022
MEMORANDUM FOR DISTRIBUTION C
MAJCOMs/FOAs/DRUs
FROM: DAF/SG3/4
7700 Arlington Blvd
Falls Church, VA 22042
SUBJECT: Department of the Air Force Guidance Memorandum (DAFGM) to DAFMAN 44-197,
Military Drug Demand Reduction Program
By Order of the Secretary of the Air Force, this Department of the Air Force Guidance
Memorandum immediately implements changes to Air Force Manual (AFMAN) 44-197, Military
Drug Demand Reduction Program. Compliance with this Memorandum is mandatory. To the extent
its direction is inconsistent with other Air Force publications, the information herein prevails in
accordance with Department of the Air Force Instructions (DAFI) 90-160, Publications and Forms
Management.
This Memorandum immediately changes the publication title from an Air Force Manual
(AFMAN) to a Department of Air Force Manual (DAFMAN) to expand applicability to include the
U.S. Space Force (USSF). It updates the prohibition on the use and ingestion of hemp products,
including but not limited to cannabidiol (CBD). The Memorandum also mandates use of the annual
compliance tool to achieve the required annual testing rate; updates the training requirements for
Air National Guard Medical Review Officers; and updates Drug Demand Reduction collections
procedures and staffing requirements.
This Memorandum becomes void after one year has elapsed from the date of this
Memorandum, or upon publication of an Interim Change or rewrite of DAFMAN 44-197,
whichever is earlier.
SHARON R. BANNISTER
Major General, USAF, DC
Director, Medical Operations
Office of the Surgeon General
